Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $10,471,246.56 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 115,056 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $91.01, for a total transaction of $10,471,246.56. Following the sale, the director directly owned 647,914 shares in the company, valued at approximately $58,966,653.14. This represents a 15.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The shares were sold at an average price of $98.52, for a total transaction of $24,268,431.60.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total transaction of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total transaction of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The shares were sold at an average price of $103.75, for a total transaction of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.08, for a total transaction of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00.
• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.10, for a total transaction of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.95, for a total transaction of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.97, for a total value of $374,185.23.

Kymera Therapeutics Stock Performance

KYMR traded up $9.02 during mid-day trading on Monday, reaching $99.45. The stock had a trading volume of 2,891,041 shares, compared to its average volume of 589,977. The stock has a market capitalization of $8.18 billion, a P/E ratio of -27.86 and a beta of 2.02. The firm’s fifty day simple moving average is $83.41 and its two-hundred day simple moving average is $81.31. Kymera Therapeutics, Inc. has a 52 week low of $36.65 and a 52 week high of $105.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.82) earnings per share. As a group, analysts expect that Kymera Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KYMR. Empowered Funds LLC bought a new position in shares of Kymera Therapeutics during the 1st quarter valued at about $203,000. Glenmede Trust Co. NA increased its stake in Kymera Therapeutics by 3.6% during the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after purchasing an additional 235 shares in the last quarter. Amundi bought a new stake in Kymera Therapeutics during the 1st quarter worth approximately $249,000. California State Teachers Retirement System raised its holdings in Kymera Therapeutics by 23.0% during the 1st quarter. California State Teachers Retirement System now owns 56,282 shares of the company’s stock worth $4,688,000 after buying an additional 10,540 shares during the period. Finally, Eagle Health Investments LP raised its holdings in Kymera Therapeutics by 7.0% during the 1st quarter. Eagle Health Investments LP now owns 145,816 shares of the company’s stock worth $12,145,000 after buying an additional 9,516 shares during the period.

Wall Street Analyst Weigh In

KYMR has been the subject of a number of recent research reports. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 8th. Citigroup raised their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. BTIG Research dropped their target price on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $119.00 price target on shares of Kymera Therapeutics in a research note on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $117.14.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.